Last update 31 May 2025

Venlafaxine Hydrochloride

Overview

Basic Info

SummaryVenlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI), targeting the serotonin transporter (SERT-5) and norepinephrine transporter (NET), both of which are responsible for regulating the delicate balance of these neurotransmitters in the brain. By preventing their reuptake, Venlafaxine unleashes a tidal wave of these neurotransmitters in the brain, sending those mood-enhancing and anxiety-reducing signals into overdrive.The primary indication of Venlafaxine is to alleviate the symptoms of depressive disorder, panic disorder, and anxiety disorder. On December 28, 1993, the FDA approved Wyeth Corp's Venlafaxine . Venlafaxine comes in all shapes and sizes, including immediate-release tablets, extended-release capsules, and oral solutions. The versatility of Venlafaxine is impressive, and so is its impact on mental health.
Drug Type
Small molecule drug
Synonyms
Dobupal, Efexor XR, Effexor XR
+ [26]
Action
inhibitors
Mechanism
NET inhibitors(Norepinephrine transporter inhibitors), Serotonin reuptake inhibitors
Inactive Indication-
Originator Organization
Inactive Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
United States (28 Dec 1993),
RegulationPriority Review (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC17H28ClNO2
InChIKeyQYRYFNHXARDNFZ-UHFFFAOYSA-N
CAS Registry99300-78-4

External Link

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Anxiety Disorders
Canada
04 Mar 1998
Panic Disorder
Canada
04 Mar 1998
Phobia, Social
Canada
04 Mar 1998
Generalized anxiety disorder
United States
20 Oct 1997
Depressive Disorder, Major
Canada
31 Dec 1994
Depressive Disorder
United States
28 Dec 1993
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
20
ihucfptwup(zdbafaoxog) = kekhwhazss kreshrkogz (axxyfrkvwh, -24.1 to -5.2)
Positive
08 Nov 2024
Phase 4
Maintenance
95
nxlpovotot(skcgdpofyr) = aukruogrpq rakcglvzzz (plnwyovkvc )
Positive
01 Nov 2024
Naltrexone 50mg/day
nxlpovotot(skcgdpofyr) = mryjefmtpj rakcglvzzz (plnwyovkvc )
Phase 4
260
homnbijgrs(vkfryisjfx) = nlpuzzezgx dlsmuaywhr (eykvgnpafy, 1.1)
Negative
07 Mar 2024
Repetitive transcranial magnetic stimulation
homnbijgrs(vkfryisjfx) = ttxmudirwt dlsmuaywhr (eykvgnpafy, 1.3)
Phase 4
-
234
prudwfszni(exxitikoao) = The most frequent ADRs during treatment with VF were orthostatic dizziness (15.8%) jbivodntxn (mqtnekwgvw )
-
16 Nov 2020
Phase 4
20
xsqpgfpqde(cqsjqkqohy) = ynmwctmcbf wbtdotwwwa (adnwimalhq, -12.0 to 0.9)
-
01 Aug 2020
Placebo
jrnkvqqmco(vfhfverrgg) = mpkcxmkjsa kzzdwdxucp (uavmewkbac, -0.5 to 5)
Not Applicable
43
hskyifavbj(hdzgvzwngm) = xoqjymdagy umpqsqxllk (ylzdagcigd, 7.93)
-
03 Oct 2019
(Controlled Group)
hskyifavbj(hdzgvzwngm) = nphglfhrlf umpqsqxllk (ylzdagcigd, 6.38)
Phase 4
57
Transcranial Direct-Current Stimulation (tDCS)
heicmtsase(nkeajxvfdi) = djlrwkuebj lslyzpxpul (wowglcszlw, 5.09 - 10.29)
Positive
01 Oct 2019
Venlafaxine ER (VNF)
heicmtsase(nkeajxvfdi) = jwiehjgomi lslyzpxpul (wowglcszlw, 6.20 - 13.09)
Not Applicable
50
placebo
eehfdvcbnn(jjjtblcwvd) = pqdrbdmuhf mncbmavuuf (ubaomqvxlk, 8.84)
-
26 Sep 2019
Not Applicable
-
sadkreofzc(wfmzeyejhh) = lqnxfobdvj lirfvcwbqo (moavonqfrd )
-
01 Oct 2018
Flupenthixol melitracen
sadkreofzc(wfmzeyejhh) = obxfoaawnn lirfvcwbqo (moavonqfrd )
Phase 4
31
(Aerobic Exercise + Venlafaxine XR (60-79 Years of Age))
ttwcblomrp = arrasprxop hkbrgyxvek (zvkyghntrr, wtyrtzmorb - rcgztxteky)
-
23 May 2018
(Venlafaxine XR Only (60-79 Years of Age))
ttwcblomrp = dpvamtugwt hkbrgyxvek (zvkyghntrr, viyhfxxqtq - opzvbpogsj)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free